PRESS RELEASE published on 03/20/2024 at 09:50, 1 year 2 months ago MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
PRESS RELEASE published on 03/20/2024 at 09:50, 1 year 2 months ago MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRIEF published on 03/04/2024 at 11:05, 1 year 3 months ago MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRIEF published on 03/04/2024 at 11:05, 1 year 3 months ago MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
PRESS RELEASE published on 03/04/2024 at 11:00, 1 year 3 months ago MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRIEF published on 02/26/2024 at 10:30, 1 year 3 months ago MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression Depression MB22001 Essai Clinique MindBio Microdosage
BRIEF published on 02/26/2024 at 10:30, 1 year 3 months ago MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression Depression MB22001 MindBio Microdosing Clinical Test
PRESS RELEASE published on 02/26/2024 at 10:30, 1 year 3 months ago MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
PRESS RELEASE published on 02/14/2024 at 10:00, 1 year 4 months ago MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
PRESS RELEASE published on 01/30/2024 at 08:10, 1 year 4 months ago MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD
Published on 06/14/2025 at 16:25, 1 day 7 hours ago New to The Street Episode #671 Airs Tonight on Bloomberg Television at 6:30 PM EST Featuring FLOKI, Arrive AI (NASDAQ: ARAI), Health In Tech (NASDAQ: HIT), Vita Bella, and NRX Pharmaceuticals (NASDAQ: NRXP)
Published on 06/14/2025 at 02:00, 1 day 21 hours ago Battery X Metals Validates Provisional Patent Applications Filed with the United States Patent and Trademark Office Through Successful Real-World Trials of Next-Generation Lithium-Ion Battery Rebalancing Machine
Published on 06/14/2025 at 01:05, 1 day 22 hours ago Diamcor Receives Section 244 Notice from Tiffany & Co.
Published on 06/13/2025 at 19:10, 2 days 4 hours ago Allane Mobility Group records growth in operating business in 2024
Published on 06/13/2025 at 18:47, 2 days 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/13/2025 at 18:47, 2 days 5 hours ago Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:42, 2 days 5 hours ago Funding Circle Holdings plc: HOL-Holdings in Company - AMENDED
Published on 06/13/2025 at 18:00, 2 days 5 hours ago BOA CONCEPT: Mise à disposition des documents préparatoires de l’Assemblée Générale du 26 juin 2025
Published on 06/13/2025 at 18:07, 2 days 5 hours ago Déclaration des transactions sur actions propres réalisées du 2 juin au 6 juin 2025
Published on 06/13/2025 at 18:07, 2 days 5 hours ago Disclosure of trading in own shares between June 2nd and 6th, 2025
Published on 06/13/2025 at 09:55, 2 days 13 hours ago Déclaration d'actions et de droits de vote au 31.05.2025